Women's bone health
- Preventative care for women 30+
- Post-pregnancy structural recovery
- Peri- & menopausal density support
- Osteopenia management
Pharmacy · Clinic · D2C
Exclusive UK distribution
Bone health, engineered
from the inside out.
Matrix Bioscience Ltd holds exclusive UK distribution rights for STEOSIL® — a clinically supported, next-generation bone-health formulation built around Mesoporosil®, a highly bioavailable silicon delivery system, plus Vitamin K2 and D3.
The hero ingredient
Meet Mesoporosil®.
380×
more soluble than conventional silicon supplements — the bioavailability behind every measurable outcome.
Conventional silicon supplements are poorly absorbed and rarely translate into measurable skeletal benefit. Mesoporosil® is a next-generation silicon delivery system — the form clinically shown to drive osteoblast activity, collagen type I synthesis and cross-linking in human cells.
Inside STEOSIL®, Mesoporosil® sits alongside Vitamin K2 (MK-7) and Vitamin D3 — a synergistic triplet that supports calcium absorption, directs minerals into bone matrix, and reinforces the collagen scaffold those minerals are deposited onto.
01 / FORM
Bioavailable silicon
Delivered as orthosilicic acid — the only form clinically demonstrated to meaningfully stimulate osteoblast activity and collagen markers.
02 / ACTION
Collagen scaffold support
Stimulates type I collagen synthesis and reinforces cross-linking — the protein framework on which bone minerals are deposited.
03 / SYNERGY
Triple-active formulation
Combined with Vitamin D3 (calcium absorption) and Vitamin K2 (matrix-directed mineralisation) for measurable, additive benefit.
04 / DOSE
One tiny tablet, once a day
Designed for consumer compliance — the entire active load delivered in a single, easy-to-swallow tablet.
Clinical evidence
Science of STEOSIL®
STEOSIL® is built on the published literature for bioavailable silicon, Vitamin K2 and D3 in bone metabolism — in vitro mechanism, observational cohorts, and randomised supplementation studies.
Cell-culture · MG-63 osteoblasts
+77.6%
Collagen type I synthesis with orthosilicic acid + D3 + K2 vs. control.
Triple-active in vitro · Gu, 2022
Cell-culture · MG-63 osteoblasts
+48.4%
Osteocalcin synthesis — a key marker of new-bone formation — vs. control.
Triple-active in vitro · Gu, 2022
Fracture-healing clinical group
84.6%
Of patients achieved early removal of orthoses with silicon supplementation — vs. 15.4% control.
MR imaging study · Sildì group
Population BMD · Framingham
up to 10%
Higher hip BMD in highest vs. lowest dietary silicon quintile (men & premenopausal women).
J Bone Miner Res, 2004 · n=2,847
Mechanism summary
Collagen is the bricks.
STEOSIL® is the binder.
Collagen forms the bone framework — type I collagen alone makes up roughly 85–90% of the organic matrix. Without the right biochemical support, that scaffold cannot properly assemble, stabilise or cross-link. STEOSIL® supplies exactly that support: collagen synthesis pathways, cross-linking, mineralisation cofactors. The result is a more resilient bone matrix — not just more calcium.
Format & presentation
Tiny tablet.
Retail-ready.
STEOSIL® ships as the lead format — a small, once-daily tablet in a premium blister pack — with a soft-gel capsule available as a secondary option for partners who prefer it.
Target markets
Three high-growth
consumer segments.
Bone-health demand is no longer niche or age-gated. STEOSIL® positions cleanly across women’s preventative wellness, performance recovery, and active-longevity — in pharmacy, clinic, sports and premium e-commerce.
Sports & performance recovery
- High-impact athletes — football, rugby, run
- Stress-fracture rehab
- Return-to-play protocols
- Team & club nutrition programmes
Clubs · Performance · Specialist retail
Active lifestyle & longevity
- Healthy ageing & lifelong mobility
- Joint & bone-matrix protection
- Skeletal resilience
- Longevity & healthspan stacks
Wellness · Longevity · Subscription
Why partner
Six reasons to trade
STEOSIL® with us.
We’re the only authorised UK route to STEOSIL®. We supply premium UK brands, pharmacies, clinics and sports programmes ready to put a science-led bone health product on shelf without building it from scratch.
01
Exclusive UK rights
Sole authorised UK distributor — no parallel routes, no channel conflict, full territorial protection for committed partners.
02
Retail-ready supply
Premium blister packs, shipped shelf-ready. Minimum time-to-market — pitch deck to point-of-sale in weeks, not quarters.
03
Science-led positioning
Peer-reviewed evidence base for Mesoporosil®, K2 and D3 in bone metabolism — defensible claims, premium price point.
04
One tablet a day
Tiny, easy-to-swallow tablet — the entire daily load in a single dose. Compliance you can build subscription around.
05
Omni-channel fit
Pharmacy, clinic, sports performance, longevity D2C — one SKU sits cleanly across every premium UK channel.
06
Co-marketing support
Clinical dossier, formulation deck, claims toolkit and partner-ready brand assets — ready to plug into your marketing pipeline.
Trade enquiries
Talk to us about
distribution.
For UK retail, pharmacy, clinical, sports and D2C partners. Drop in your details and a brief outline of fit — we’ll come back within two business days with the partner pack and price tiers.
Entity
Matrix Bioscience Ltd · UK
Trade
UK only · exclusive STEOSIL®
Response
Within 2 business days
Quality
Every batch tested · CoAs on request
Frequently asked
Trade partner
questions.
If something isn’t covered here, send us an enquiry — full clinical, regulatory and supply documentation is available under NDA.
Contact us →What is STEOSIL® and what makes it different?
STEOSIL® is a next-generation bone-health supplement built around three actives: Mesoporosil® (highly bioavailable silicon delivered as orthosilicic acid), Vitamin K2 (MK-7) and Vitamin D3. Unlike most bone supplements, it doesn’t just supply calcium — it supports the collagen matrix calcium is deposited onto.
How is Mesoporosil® different from other silicon supplements?
Mesoporosil® is roughly 380× more soluble than conventional silicon supplements. Orthosilicic acid is the only form clinically demonstrated to meaningfully stimulate osteoblast activity and collagen synthesis — bioavailability is the whole story.
Are the products batch-tested? Can you provide CoAs?
Yes — every batch is independently laboratory-tested for active content, heavy metals, microbiological purity and identity. A full Certificate of Analysis (CoA) is issued per batch and supplied on request to all trade partners.
Manufacturing is conducted in EU GMP-compliant facilities with full traceability from raw material to finished pack.
What format and dosage do you ship?
Lead format is a small, easy-to-swallow tablet — one tablet, once daily, oral. Each tablet contains 100 mg Mesoporosil®, 45 µg Vitamin K2 (MK-7) and 30 µg (1200 IU) Vitamin D3. A soft-gel capsule version is available as a secondary format.
Standard pack is 30 units in a premium blister + folding carton, shelf-ready.
Is the product UK and EU regulatory compliant?
STEOSIL® is classified as a food supplement and complies with applicable UK and EU regulations including Regulation (EC) 1169/2011 on food information to consumers. Full regulatory documentation is available to trade partners under NDA.
What is the shelf life and storage requirement?
24 months from manufacture, stored in a cool dry place at no more than 25°C and out of direct sunlight.
Which channels can I distribute STEOSIL® through?
Premium pharmacy, independent pharmacy, clinic and practitioner channels, sports and performance organisations, specialist wellness retail, and D2C / e-commerce. We work with one committed partner per channel where it makes sense — talk to us about territorial fit.
How do we open a trade account?
Submit a trade enquiry via the contact form. We’ll come back within two business days with the partner pack, price tiers, lead times and the full clinical / regulatory dossier.